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Abstract
Introduction: For patients with rheumatoid arthritis (RA) whose treatment with a tumour necrosis factor inhibitor
(TNFi) is failing, several biological treatment options are available. Often, another TNFi or a biological with another
mode of action is prescribed. The objective of this study was to compare the effectiveness and cost-effectiveness
of three biologic treatments with different modes of action in patients with RA whose TNFi therapy is failing.
Methods: We conducted a pragmatic, 1-year randomised trial in a multicentre setting. Patients with active RA
despite previous TNFi treatment were randomised to receive abatacept, rituximab or a different TNFi. The primary
outcome (Disease Activity Score in 28 joints) and the secondary outcomes (Health Assessment Questionnaire Disability
Index and 36-item Short Form Health Survey scores) were analysed using linear mixed models. Cost-effectiveness
was analysed on the basis of incremental net monetary benefit, which was based on quality-adjusted life-years
(calculated using EQ-5D scores), and all medication expenditures consumed in 1 year. All analyses were also
corrected for possible confounders.
Results: Of 144 randomised patients, 5 were excluded and 139 started taking abatacept (43 patients), rituximab
(46 patients) or a different TNFi (50 patients). There were no significant differences between the three groups with
respect to multiple measures of RA outcomes. However, our analysis revealed that rituximab therapy is significantly
more cost-effective than both abatacept and TNFi over a willingness-to-pay range of 0 to 80,000 euros.
Conclusions: All three treatment options were similarly effective; however, when costs were factored into the
treatment decision, rituximab was the best option available to patients whose first TNFi treatment failed. However,
generalization of these costs to other countries should be undertaken carefully.
Trial registration: Netherlands Trial Register number NTR1605. Registered 24 December 2008.
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Introduction
In many countries, a tumour necrosis factor inhibitor
(TNFi) such as adalimumab, certolizumab, etanercept,
golimumab or infliximab is indicated for treating patients
with rheumatoid arthritis (RA) who have moderate to high
disease activity and whose treatment with methotrexate
and at least one other conventional synthetic disease-
modifying antirheumatic drug (csDMARD) has failed.
However, according to the European League Against
Rheumatism (EULAR), 30% to 50% of all patients treated
initially with a first TNFi do not respond to treatment
(that is, treatment failure); moreover, 20% to 45% of all pa-
tients discontinue treatment within 1 year [1-3]. Until re-
cently, the best treatment option after previous TNFi
treatment failure was to begin therapy with a different
TNFi, a strategy that has proven effective regardless of the
reason for the change in treatment [4-10]. However, after
the failure of one TNFi, biologic disease-modifying anti-
rheumatic drugs with a different mode of action can
also be considered. Examples of these include abatacept,
rituximab and tocilizumab. These biologic agents have
high clinical effectiveness compared with placebo and
csDMARDs. In addition, they have a good safety profile,
[11-13] and are approved for RA treatment in the
Netherlands and Belgium. In a recent study, researchers
indirectly compared randomised controlled trials and
found no difference in effectiveness between abatacept,
rituximab and a second TNFi therapy in patients whose
treatment with a first TNFi failed [14,15]. However, a
difference in effectiveness cannot be excluded with cer-
tainty, as no direct comparison was performed, and all
three treatment options differ with respect to their tar-
get and mechanism of action. Moreover, differences in
the mode and frequency of delivery can result in a con-
siderable variation in treatment costs. For example, aba-
tacept and TNF inhibitors have fixed frequencies of
administration, whereas rituximab can be given every
6 months or as dictated by disease activity. The object-
ive of this study was to compare the effectiveness and
cost-effectiveness of three treatment regimens (abata-
cept, rituximab or a different TNFi) after previous TNFi
treatment failure in patients with RA.
Methods
Study design
A pragmatic multicentre randomised trial was performed
to compare the effectiveness and cost-effectiveness of
treating patients with abatacept, rituximab or a TNFi.
Tocilizumab was not included, because it was not licensed
at the start of the study. Using a web-based programme,
patients with RA whose previous treatment with a TNFi
failed were randomly assigned to receive rituximab, abata-
cept or a different TNFi (at a randomisation ratio of 1:1:1).
Treatment failure was defined as either the physician or
patient terminating the initial TNFi treatment. The rea-
sons to terminate treatment included ineffectiveness or
the onset of adverse events. In the randomisation protocol,
each hospital was considered as a stratum, because pa-
tients in academic, teaching and general hospitals could
be different and should be equally divided. Thereafter,
treatment was not set to a specific protocol and was
therefore provided at the discretion of the treating phys-
ician. Consistent with a pragmatic trial, care providers,
participants and assessors were not blinded with respect
to the treatment given. This study was approved by the
Arnhem-Nijmegen regional ethics committee.
Participants
Patients who met the following criteria were included in
the study: previous treatment failure with their first TNFi,
moderate to high disease activity (Disease Activity Score
in 28 joints (DAS28) >3.2) and no previous treatment with
abatacept or rituximab. Patients were excluded if they had
a contraindication for treatment (for example, pregnancy,
the presence of a serious infection) based on the rheuma-
tologist’s judgment of if they had a strong preference or
dislike for one of the treatment agents or did not want to
be randomized. Patients were included between 2009 and
2012. Each patient signed an informed consent form for
participation in this study.
Interventions
The intervention was a treatment protocol using abata-
cept, rituximab or a different TNFi than the previous
TNFi treatment. At the time of this study, five TNF in-
hibitors were available. The choice of TNFi was left to
the discretion of the patient in the TNFi group and the
patient’s treating physician. In general, the patients began
their treatment with the Dutch or Belgian registered dose
as follows: adalimumab was administered at 40 mg every
2 weeks; etanercept was administered at 50 mg per week
or 25 mg twice per week; infliximab was administered at
3 mg/kg every 8 weeks after a loading dose given at weeks
0, 2 and 6; golimumab was administered at 50 mg every
4 weeks; and 400 mg of certolizumab was administered in
weeks 0, 2 and 4, followed by a 200-mg dose given every
2 weeks. The dose of abatacept was based on the patient’s
body weight as follows: patients who weighed <60 kg re-
ceived 500 mg, patients weighing 60 to 100 kg received
750 mg and patients who weighed >100 kg received
1,000 mg. The doses were delivered by infusion over
1 hour every 4 weeks. Rituximab was administered by in-
fusion (1,000 mg) at weeks 0 and 2. A second course could
be administered after 6 months in patients who responded
to the first course. The timing of the retreatment course
depended on the increase in disease symptoms and activ-
ity and was at the discretion of the physician and patient.
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All treatment options could be administered in combin-
ation with a csDMARD or corticosteroid.
Outcomes
The primary outcome for effectiveness was the DAS28
[16] over time. The secondary outcome measures were
functional ability measured using the Health Assessment
Questionnaire Disability Index (HAQ-DI) [17] and gen-
eric descriptive quality of life (36-item Short Form
Health Survey (SF-36)) [18]. All effectiveness outcomes
were measured at 0, 3, 6, 9 and 12 months. The out-
comes for the cost-effectiveness analysis were medica-
tion costs and quality-adjusted life-years (QALYs) over a
12-month period. QALYs were based on utilities (a nu-
meric value ranging from 0 to 1.0, reflecting health sta-
tus: 0 indicates death, and 1.0 indicates the best health
imaginable) calculated using the trapezium rule. The
trapezium rule is a way of estimating the area under a
curve. We know that the area under a curve is given by
integration, so the trapezium rule gives a method of es-
timating integrals. The trapezium rule works by splitting
the area under a curve into a number of trapeziums
whose area we know [19]. The utilities were calculated
using the EQ-5D score [20]. The EQ-5D is a generic
measure of health status that provides a simple descrip-
tive profile and a single index value that can be used in
the clinical and economic evaluation of health care and
in population health surveys. This questionnaire con-
sists of five questions attending to five dimensions: mo-
bility, self-care, usual activities, pain/discomfort and
anxiety/depression. Each dimension has three levels: no
problems, some problems and extreme problems [20,21].
Furthermore, all medication-related information was re-
corded, including the type of medication, start date, dose,
stop date, change in medication and/or dose, and the rea-
son for the change. Medication prices were obtained from
the Dutch National Information Centre [22] in October
2013 and from the hospital pharmacist at Radboud
University Medical Centre, Nijmegen, the Netherlands.
All prices were adjusted to 2013, and additional costs
were calculated for the infusion costs for the intramural
treatments with full-cost pricing (see Additional file 1).
Sample size
The three treatment options (abatacept, rituximab and
TNFi) were considered equivalent if the two-sided 95%
confidence interval (CI) showed that the treatments
were at least not more than 0.4 DAS28 values better or
worse than the comparator, using analysis of covariance
on the mean DAS28 of 6, 9 and 12 months. The equiva-
lence margin of 0.4 is one-third of a population standard
deviation (SD = 1.2) and two-thirds of a minimal clinically
important difference (0.6) for an individual patient [23].
Efficiency can be gained by analysing repeated measures;
therefore, the SD can be adjusted using the correlation
between the repeated measures [24]. The correlation
was 0.70 between repeated DAS28 measures based on
results from an inception cohort of patients with newly
diagnosed RA, and the SD was 1.2 [24,25], which results
in a SD of 0.67. This SD is used in a standard formula
for noninferiority power calculations for continuous
outcomes [26], leaving 44 evaluable patients per group
required for 80% power to show noninferiority within
the margin of 0.4 (see [27]).
Statistical analyses
The results were analysed in accordance with the
intention-to-treat principle, meaning that all patients
were analysed in the medication group in which they
initially started, regardless of whether they received and/or
adhered to that treatment for the full 12 months. We ex-
cluded patients who were initially assigned to a treatment
group but chose to continue taking their first TNFi treat-
ment, patients who chose not to participate in the study
and patients who developed a contraindication (and there-
fore no longer fulfilled the selection criteria).
The primary clinical outcome (mean DAS28) was ana-
lysed over time using linear mixed models. If a DAS28
score was missing because the erythrocyte sedimentation
rate (ESR) was missing, the ESR was imputed based on
other ESR values, the swollen joint count score, the ten-
der joint count score, the Visual Analogue Scale score of
the patient’s general health, age, and sex [28]. To handle
missing baseline measurements (and therefore increase
power), the missing indicator method was used in linear
mixed models analyses [29]. Because there was coinciden-
tal unbalanced allocation in some observed variables, both
corrected and uncorrected analyses were performed. In
the corrected analyses, variables were added to the linear
mixed model if they had a P-value <0.2 in the univariate
analyses (one-way analysis of variance, Kruskal-Wallis test
or χ2 test) and if they changed the β-coefficient of the vari-
able ‘medication’ (abatacept, rituximab or TNFi) by >10%
(a standard rule of thumb for this type of analysis). The
analyses were repeated for the HAQ-DI, the SF-36 com-
ponent scales and the EQ-5D scores. Moreover, the per-
centages of patients in remission (DAS28 <2.6) and low
disease activity (DAS28 <3.2 and >2.6) and the percentages
of patients with a good or moderate EULAR response
were analysed at 6 and 12 months [30].
‘Drug survival’ (that is, time to drug discontinuation)
was analysed with Kaplan-Meier and Cox proportional
hazards models to correct for possible confounders. Drug
survival was analysed only between TNFi and abatacept,
because rituximab follow-up infusions were given on de-
mand and a stop date was difficult to define.
A cost-effectiveness analysis was performed based on a
time frame of 1 year. Medication costs are believed to be
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the principal incremental cost drivers in RA care for pa-
tients who use biologic treatments. Therefore, the costs
used in the economic evaluation were based on the costs
of the medications and the costs associated with intra-
mural infusion of infliximab, rituximab or abatacept (see
Additional file 1). The net monetary benefit (NMB) statis-
tic was used because this is a regression-based approach
to analysis of cost-effectiveness and can correct for con-
founders. NMB can be calculated as follows: NMB
= (WTP × Effects) −Costs, where WTP is willingness to
pay (in euros). Incremental NMB (INMB) is the difference
between one NMB and another NMB. We used the fol-
lowing five threshold values for WTP for each QALY
gained: 0, 20,000, 40,000, 60,000 and 80,000 euros. Ac-
cording to the decision rule, the option with the highest
NMB is the most cost-effective, given that specific WTP.
Confounders were taken into account as described above.
The results were based on a general linear model that was
bootstrapped 1,000 times to correct for uncertainty.
Results
In our study, we randomly assigned 144 patients to one of
three treatment arms—abatacept, rituximab or TNFi—and
206 patients were switched to another biologic treatment
in the same period but did not participate in the study.
Figure 1 provides an overview of patient selection, as well
as the exclusion criteria that were applied throughout the
study. Five patients did not begin taking their randomly
assigned treatment; the reasons are shown in Figure 1.
Therefore, 139 patients were ultimately included in the
analyses. The TNFi group (n = 50) included patients who
took adalimumab (n = 21), etanercept (n = 19), infliximab
(n = 5), golimumab (n = 3) or certolizumab (n = 2). Figure 1
also shows that 59 patients stopped taking the medica-
tion or switched from their assigned treatment within
1 year—35 due to ineffectiveness, 14 due to side effects
and 5 for other reasons—with median (interquartile range)
durations on therapy of 6 (3 to 8) months, 2 (1 to 7)
months and 6 (3 to 8) months, respectively. The patient
baseline characteristics and comedications are summarised
in Table 1. Both rheumatoid factor (RF) and sex differed
between the three groups (P <0.2) and were therefore seen
as possible confounders.
Treatment effectiveness
The mean (SD) DAS28 scores at 12 months were 3.8
(1.2) for abatacept, 3.4 (1.2) for rituximab and 3.5 (1.5)
for TNFi (Figure 2a). Figure 3 presents the percentage of
Figure 1 Inclusion and exclusion of patients in the study. aba, abatacept; rit, rituximab; TNF, Tumour necrosis factor; TNFi, Tumour necrosis factor
inhibitor; toc, tocilizumab.
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patients in remission, low disease activity and EULAR
good or moderate response at 6 and 12 months for the
three groups. There were no significant differences be-
tween the three treatment groups with respect to DAS28,
HAQ-DI, EQ-5D or SF-36 over time (analysed using lin-
ear mixed models that were either uncorrected or cor-
rected for RF and sex) (see Figure 2).
Drug survival
The 1-year drug survival between TNFi and abatacept
was not significantly different for either the corrected
analyses (expβ = 0.697, 95% CI = 0.369 to 1.318, P = 0.267)
or the uncorrected analyses (expβ = 0.870, 95% CI = 0.489
to 1.546, P = 0.635).
Safety
Fifty-one patients (36.7%) in the study reported at least
one adverse event at 1 year (16 in the abatacept group,
15 in the rituximab group and 20 in the TNFi group)
(see Table 2). One suspected unexpected serious ad-
verse reaction (SUSAR) occurred within 1 year. This
patient, who was in the abatacept group, became psych-
otic 4 months after the start of the study. However, in
retrospect, this SUSAR did not appear to be related to
the medication.
Cost-effectiveness
In our analysis of cost-effectiveness, the costs were
dependent upon the medication used, the dose delivered,
the method of delivery and the frequency of administra-
tion. In the abatacept group, 3% of the patients started
with a 500-mg dose, 84% started with a 750-mg dose and
13% started with a 1,000-mg dose. All of these patients
started treatment with a frequency of one dose every
4 weeks. All of the patients in the rituximab group started
at the recommended dose of two doses of 1,000 mg. Eight
patients stopped the rituximab treatment and switched to
another biologic (see Figure 1), eight patients did not stop
but also did not receive a second dose within 1 year, and
thirty patients did receive a second dose. The mean
interval between the first and second rituximab treat-
ments was 9 months (11 patients received their second
dose at 6 months). In the TNFi group, all of the patients
except one started at the recommended dose and fre-
quency; this patient took adalimumab weekly rather than
once every 2 weeks.
The 1-year mean QALYs and medication-related costs
(in euros) are presented in Figure 4. The uncorrected
difference in cost was significant between the abatacept
and rituximab groups (mean difference = €5,586, 95%
CI = €3,681 to €7,491, P <0.001) and between the TNFi
and rituximab groups (mean difference = €3,758, 95%
CI = €1,661 to €5,856, P = 0.001), but not between the
TNFi and abatacept groups (mean difference = €1,828,
95% CI = −€294 to €3,950, P = 0.090).
A positive INMB can be interpreted as the added value
(in euros) of following one treatment versus another.
When uncorrected and corrected for sex and RF, over a
WTP range of 0 to 80,000 euros per QALY, INMB was
significantly different between the rituximab and abata-
cept groups (P <0.001) and between the rituximab and
TNFi groups (P <0.05), as the INMB of zero did not fall
within the 95% CI (that is, the zero data point on the y-
axis was below the dashed lines) (see Figure 5). In con-
trast, the difference between abatacept and TNFi was not
significant over the entire WTP range from 0 to 80,000
euros per QALY (that is, the lower 95% CI fell below 0
INMB over the entire WTP range). However, TNFi had a
Table 1 Patient characteristics at baselinea
Abatacept (n = 43) Rituximab (n = 46) TNFi (n = 50) Total (n = 139) P-value
Mean age (SD), yr 56.16 (9.95) 57.09 (11.08) 55.81 (12.53) 56.34 (11.24) 0.852
Female sex, % 88.4 (n = 38) 63.0 (n = 29) 74.0 (n = 37) 74.8 (n = 104) 0.022
Median disease duration (IQR), yr 6.56 (2.56 to 11.96) 7.60 (3.22 to 16.25) 5.64 (1.79 to 12.00) 6.25 (2.43 to 14.30) 0.174
RF-positive, % 56.4 (n = 22) 80.0 (n = 36) 62.5 (n = 30) 66.7 (n = 88) 0.054
Mean DAS28 (SD) 4.74 (1.46) 4.87 (1.24) 4.92 (1.11) 4.84 (1.26) 0.805
Mean HAQ-DI (SD) 1.46 (0.64) 1.39 (0.71) 1.37 (0.65) 1.40 (0.66) 0.822
Median previous csDMARDs (IQR), n 2 (2 to 3) 3 (2 to 3) 2 (2 to 3) 2 (2 to 3) 0.192
Comedication, % 0.894
csDMARD + Corticosteroidb 20.9 (n = 9) 28.3 (n = 11) 28.0 (n = 14) 25.9 (n = 36)
csDMARDb 41.9 (n = 18) 50.0 (n = 23) 38.0 (n = 19) 43.2 (n = 60)
Corticosteroid 11.6 (n = 5) 8.7 (n = 4) 10.0 (n = 5) 8.6 (n = 12)
None (biologic monotherapy) 25.6 (n = 11) 17.4 (n = 8) 24.0 (n = 12) 22.3 (n = 31)
acsDMARD, Conventional synthetic disease-modifying antirheumatic drug; DAS28, Disease Activity Score in 28 joints; HAQ-DI, Health Assessment Questionnaire
Disability Index; IQR, Interquartile range; RF, Rheumatoid factor; SD, Standard deviation. bOf the patients who took the biologic in combination with a csDMARD,
methotrexate was the comedication in 75.0% of patients in the abatacept group, in 91.4% in the rituximab group and in 86.0% in the TNFi group.
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higher INMB than abatacept over the entire WTP range
of 0 to 80,000 euros per QALY; thus, with a WTP of 0,
40,000 and 80,000 euros, the probability of TNFi being
more cost-effective than abatacept was 97%, 75% and 50%,
respectively. The analyses performed to calculate these
percentages were uncorrected for confounders.
Discussion
The objective of this study was to compare the effective-
ness and cost-effectiveness of three standard treatments
for RA—abatacept, rituximab and TNFi—in patients with
RA whose previous TNFi treatments had failed. Our ana-
lysis revealed overall improvements over time, but no sig-
nificant differences between the three treatment groups
with respect to the DAS28, HAQ-DI or SF-36 outcome
measures. However, we found significant differences in
the costs and cost-effectiveness of the various treatments.
Specifically, of the three treatments, rituximab was the
most cost-effective. Moreover, treating patients with a sec-
ond TNFi was more cost-effective than treating patients
with abatacept.
This study provides important clinical insights, as it is
the first study to directly compare three different treat-
ment options for patients with RA whose first TNFi treat-
ment failed. Our results are consistent with previous
indirect and observational studies regarding the effective-
ness of abatacept, rituximab and TNFi in patients with RA
whose first TNFi treatment failed their [14,15,31]. How-
ever, Finckh et al. [32], in their observational study, con-
cluded that changing to rituximab after the ineffectiveness
Figure 2 Effectiveness outcomes over time with standard deviations. (a) Disease Activity Score in 28 joints (DAS28). (b) Health Assessment
Questionnaire Disability Index (HAQ-DI). (c) EQ-5D. (d) 36-item Short-Form Health Survey (SF-36). PCS, Physical Component Summary. Month 0
represents the start of the treatment.
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of a previous TNFi is more effective than switching to an
alternative TNFi. The results of the study by Finckh
et al. can also be explained by the higher DAS28 at base-
line in the rituximab group.
Our cost-effectiveness results are consistent with
those of previous studies. For example, Malottki et al. in
the United Kingdom and Hallinen et al. in Finland used
QALYs to analyse cost-effectiveness and also concluded
that rituximab was the most cost-effective treatment
[33,34]. However, in a recent review of the cost-
effectiveness of abatacept, Athanasakis et al. reported
inconclusive results regarding the comparative cost-
effectiveness of abatacept versus rituximab [35]. Their
review also included studies that cannot be compared
directly with our study; for example, some studies used
an outcome variable other than QALYs. In our analysis,
medication-related costs were dependent upon the price,
dose, route of delivery and dosing frequency of the
Figure 3 Percentages of patients in remission, with low disease activity and with good or moderate European League Against Rheumatism
response criteria [30]. DA, Disease activity; EULAR, European League Against Rheumatism; TNFi, Tumour necrosis factor inhibitor.
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medication. These factors should be taken into account
when attempting to compare our cost-effectiveness data
with data from other countries.
A strength of our study lies in its pragmatic, rando-
mised, multicentre design [36], a design that provides a
suitable combination of internal and external validity
[37]. After randomisation (which minimises the potential
confounding by indication), treatments are provided as
normal daily clinical practice, which is often different from
strict protocols in controlled trials [3,38]. Thus, the exter-
nal validity is maximised. Moreover, in this multicentre
study, patients were recruited from a variety of hospitals
(including academic, general and teaching hospitals)
throughout the Netherlands and Belgium, with no strict
inclusion or exclusion criteria. Therefore, the results of
this study can be generalised to a broader population of
patients with RA whose first TNFi treatment failed.
The generalisability of the cost-effectiveness is more
difficult because every country has its own agreements
about treatment prices. However, the main cost driver is
the cost per milligram of (biologic) treatment. By using
the data regarding doses, frequencies, means of delivery
and prices of the medications provided in this article, costs
can be calculated for other countries and compared with
our results.
This study also has some limitations. First, we did not
include tocilizumab therapy as a treatment arm, as this
treatment option was not licensed at the start of the study.
Tocilizumab has been reported to be effective for treating
RA [13], and its effectiveness is similar to that of other
biologic treatments [39] when given to patients whose first
TNFi treatment has failed [14,40]. The dose—and thus the
cost—of administering tocilizumab is dependent upon
body weight. For example, for a patient weighing 70 kg,
Table 2 Adverse events reported at the 1-year follow-up examination

















Cardiovascular event 1 1 2 2 2 2 5 5
Infection 9 6 5 4 11 7 25 18
Malignancy 0 0 3 3 0 0 3 3
Laboratory abnormalitiesa 1 1 0 0 2 2 3 3
Skin condition 3 3 3 3 6 5 12 11
Gastroenterological 2 2 3 3 0 0 5 5
Otherb 5 4 7 5 7 4 19 13
Total 21 16 23 15 28 20 78 51
aLiver function test elevations and leukopenia. bIn this group, the adverse effects consisted primarily of influenza, fever, fatigue, headache and/or dizziness. One
patient in the abatacept group developed psychosis 4 months after the start of the study.
Figure 4 Mean quality-adjusted life-years and medication-related costs in a 1-year period. Error bars represent the upper bars of the 95%
confidence intervals. QALY, Quality-adjusted life-year.
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the mean annual cost is approximately 15,000 euros,
which is similar to the cost of abatacept. Thus, toci-
lizumab may be a good alternative to the treatment op-
tions evaluated in this study. However, tocilizumab has
not been compared directly with other biologic medica-
tions for treatment of RA in patients whose first TNFi
treatment failed, thus warranting the need for future
studies. A second limitation is the unequal distribution
of RF among the three treatment groups, despite our
randomisation approach. Studies have shown that rituxi-
mab yields better results in RF-positive patients (a differ-
ence of 0.3 on the DAS28 score relative to RF-negative
patients) [41,42]. In our study cohort, there were fewer
RF-positive patients than usually seen in daily clinical
practice. The rituximab group contained a higher percent-
age of RF-positive patients than the other two groups;
therefore, the effects of rituximab might have been overes-
timated. However, in daily clinical practice, rituximab is
given primarily to RF-positive patients. To control for this,
we corrected for this difference in RF positivity in our
analyses and obtained the same results for the corrected
and uncorrected analyses. It would be interesting to per-
form subgroup analyses for RF-positive patients and RF-
negative patients, but the subgroups were too small to
make valid conclusions. With respect to abatacept and
TNFi treatment, the published literature has yielded no
evidence regarding different treatment effectiveness in
RF-positive versus RF-negative patients [42,43]. A third
caveat with regard to our study is that 22% of the pa-
tients used the biologic treatment as monotherapy. This
is different from what is suggested in the literature and
provides a possible explanation for the moderate effects
over time of all three groups. However, owing to the
pragmatic trial design, this is a good representation of
daily clinical practice.
It is difficult to perform a pragmatic trial. As we can
also see in this study, it is difficult to motivate patients
to participate in pragmatic studies. Patients do not have
to participate to receive the treatments that are studied.
If they do not want to be randomised, or if they have a
preference or dislike for one specific treatment, they do
not want to be included in the study. Fortunately, in this
study, the sample size was reached because multiple hos-
pitals included patients. With regard to patient character-
istics, the patients who did not participate in the study but
did change their TNFi treatment did not differ from in-
cluded patients. Another caveat that must be considered
regards our method of calculating medication-related
costs, which included only the medication and infusion
costs in our cost-effectiveness analysis. However, we found
no difference between the groups with respect to treat-
ment effectiveness, and there seem to have been no major
differences in adverse events. If we assume that health
care–related expenses are positively related to both dis-
ease activity and the development of adverse events, we
can also assume that other health care–related costs
would be similar between the three treatment groups. Al-
though travel costs are somewhat higher for patients who
require infusion treatments (that is, the patients in the ri-
tuximab and abatacept groups), only the patients in the
abatacept group received a large number of infusions.
Nevertheless, had we included travel expenses, the cost of
treatment in the abatacept group would have been higher.
After this study was concluded, abatacept became avail-
able as an injection therapy that can be administered at
home, reducing the administration cost by an estimated
6%; therefore, treatment with abatacept can become less
expensive while providing the same effectiveness [44]. The
average costs of rituximab are lower partly because it was
provided on demand and on average a second treatment
Figure 5 Mean incremental net monetary benefit (iNMB) with 95% confidence intervals (CIs). The location of the 95% CI lines below an INMB of
zero indicates that the two treatment groups differed significantly with respect to cost-effectiveness.
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was not provided at 6 months. Still, the effectiveness was
the same as that of abatacept and TNFi. Because we study
daily clinical practice, these kind of variations are detected.
Perhaps, in the current care paradigm, abatacept and
TNFi can also be provided less frequently or in lower
doses as stated in protocols. This will then also reduce the
health care costs.
In our study, all of the treatment options (including
the various TNF inhibitors) had a good safety profile,
and the short-term (1 year) occurrence of adverse events
seems similar between the abatacept, rituximab and
TNFi treatment groups, but the numbers were too small
to perform valid statistical analyses. Aaltonen et al. [45]
showed no significant difference between TNFi and ri-
tuximab treatment in patients with serious infections
and malignancies. To make valid conclusions about the
adverse events, another study that is powered on the
adverse events should be performed. With respect to
long-term safety, van Vollenhoven et al. [46] recently
reported that long-term biologic treatment did not in-
crease the risk of any type of adverse events during
9.5 years of follow-up observations. This supports our
assertion that the treatments studied here are also likely
to be equally safe in the long run. In addition, in a re-
cent study, researchers reported that the dose of rituxi-
mab can be decreased to a single 1,000-mg dose or two
500-mg doses [47] rather than two 1,000-mg doses, as
prescribed in our study. This decrease in dose can de-
crease the cost of rituximab by almost 50% if the time to
the second dose is the same, which would greatly benefit
rituximab’s cost-effectiveness and perhaps decrease the
adverse events. With the upcoming biosimilars for rituxi-
mab and TNF inhibitors, lower costs related to those
treatments are to be expected.
Conclusions
Compared with intravenous abatacept and the various
TNF inhibitors that were tested in this study, rituximab
is the most cost-effective treatment option for patients
whose first TNFi treatment has failed. This advantage
is due primarily to the differences in drug costs; thus,
because the effectiveness and safety are the same, the
costs of the medication can drive decision making
about a biologic treatment. Considering the clinical ef-
fectiveness and costs of pharmacologic treatments after
failure of the first TNFi in patients with RA over a 12-
month period, we found that rituximab was the most
favourable treatment.
This study should be considered as an early step that
needs to be confirmed by similar analyses with larger pop-
ulations, including tocilizumab, and followed over longer
periods of time so that the social and financial costs of dif-
ferent treatment regimens are also accounted for, includ-
ing adverse events and inconvenience for patients.
Additional file
Additional file 1: Medication costs.
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